RAMAT GAN, Israel, October 22, 2018 /PRNewswire/ --
OWC PharmaceuticalResearch Corp. (OTCQB: OWCP), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced that our newly developed, highly concentrated, delivery formulation, OWC-1808, was administered
(Logo: https://mma.prnewswire.com/media/733348/OWC_Logo.jpg ) Dr. Stanley Hirsch, the Chairman of OWCP added "This is an important milestone in our pre-clinical development of cannabis-based therapies for Multiple Myeloma. This incurable blood cancer effects about 30,000 new patients a year in the USA alone. Cannabis-based therapies represent a new frontier in fighting this disease and this potentially moves cannabis from being a cancer palliative to becoming a cancer therapeutic".
About OWC Pharmaceutical Research Corp.
OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., (collectively 'OWC' or the 'Company') conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines.
OWCP is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWCP research is conducted at leading Israeli hospitals and scientific institutions and led by internationally renowned investigators. The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids and cannabis-based products for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks.
Mordechai Bignitz , Chief Executive Officer - OWC Pharmaceutical research crop, Email: Mordechai.Bignitz@owcpharma.com Tel: +972-(72)-260-8004
SOURCE OWC Pharmaceutical Research Corp.
Subscribe to our Free Newsletters!